This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
VBI Vaccines Up on Coronavirus Vaccine Candidates Selection
by Zacks Equity Research
VBI Vaccines (VBIV) selects two coronavirus vaccine candidates for clinical-stage development based on encouraging pre-clinical data.
Glaxo Receives EU Approval for Multiple Myeloma Drug Blenrep
by Zacks Equity Research
The European Commission lends a nod to Glaxo's (GSK) Blenrep as a monotherapy for patients with relapsed/refractory multiple myeloma, having received at least four previous therapies.
Pfizer (PFE) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dow Jones ETF in Focus on Index Shake-Up
by Sweta Killa
Given the tech sector dominance, many Wall Street analysts believe the post-reshuffle Dow Jones could struggle to catch up with the S&P 500 and the Nasdaq Composite, which have been hitting new highs.
Novartis' (NVS) Leukemia Drug Meets Goal in Late-Stage Study
by Zacks Equity Research
Novartis' (NVS) chronic myeloid leukemia candidate meets primary endpoint in a phase III study.
Moderna Stock Surges 260% YTD on Coronavirus Vaccine Progress
by Zacks Equity Research
Moderna (MRNA) is making significant progress in development of coronavirus vaccine. The vaccine is currently in phase III study.
Apple Stock Split Prompts Significant Changes in the Dow
by David Borun
The world's most widely referenced stock market index will soon swap out 10% of its holdings
Sarepta's Casimersen NDA Gets Priority Review From FDA
by Zacks Equity Research
Sarepta (SRPT) is seeking accelerated approval for exon 45 amenable DMD candidate, casimersen. Amondys 45 is likely to be the brand name for the candidate.
AstraZeneca Begins Coronavirus Antibody Combo Phase I Study
by Zacks Equity Research
AstraZeneca's (AZN) AZD7442 is a combination of two coronavirus-neutralizing monoclonal antibodies, AZD8895 and AZD1061.
Stock Market News for Aug 26, 2020
by Zacks Equity Research
The S&P 500 and the Nasdaq hit an all-time high on Tuesday, while the Dow declined amid mixed economic news and decline in heavy weights like Exxon Mobil and Boeing.
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
Apple Stock Split Prompts Dow Reshuffle: Who's In, Who's Out?
by Tirthankar Chakraborty
Apple's stock split reduced its weight in the Dow, prompting a shake-up in the blue-chip index, with salesforce.com, Amgen and Honeywell taking Exxon, Raytheon and Pfizer's spot.
Stock Futures Mostly Higher on Trade Talks, Dow's Shake-Up in Focus
by Zacks Equity Research
This morning, Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer had a telephonic discussion with Chinese vice premier Liu He.
Merck's Keytruda Gets Approval for Esophageal Cancer in Japan
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval in Japan as second-line treatment for esophageal squamous cell carcinoma. A new dosing regimen also receives approval in the country.
Strong Market Momentum Continues
by Zacks Equity Research
Strong Market Momentum Continues
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) submits a supplemental new drug application to the FDA seeking approval of Cabometyx in combination with Opdivo for the treatment of advanced renal cell carcinoma.
AstraZeneca Coronavirus Vaccine May Get FDA's Emergency Tag
by Zacks Equity Research
AstraZeneca's (AZN)/Oxford's AZD1222 is in phase II/III study in the UK, Brazil and South Africa with a late-stage study due to start soon in the United States with 30,000 participants.
FDA Grants Emergency Use to Plasma Therapy to Treat Coronavirus
by Kinjel Shah
Convalescent plasma contains antibodies that can fight off the disease faster and prevents COVID-19 patients from getting severely ill.
Stock Market News for Aug 24, 2020
by Zacks Equity Research
Rally in large-cap technology-related firms helped the Nasdaq hit another record high this year on Friday.
BioMarin Down on CRL From FDA for Hemophilia A Candidate
by Zacks Equity Research
BioMarin (BMRN) suffers a setback as the FDA issues a CRL to its BLA for the gene therapy Roctavian, developed to treat patients with severe hemophilia A. Shares fall as a result.
Glaxo Initiates Dosing in Phase III Meningitis Vaccine Study
by Zacks Equity Research
Glaxo (GSK) starts dosing with a phase III study on it 5-in-1 meningitis vaccine candidate.
Merck's Keytruda Positive in First-Line Esophageal Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda improves overall survival and progression-free survival compared to current standard of care in first-line metastatic esophageal cancer patients.
AstraZeneca (AZN) to Supply Coronavirus Vaccine in Europe
by Zacks Equity Research
AstraZeneca (AZN) closes a deal with the European Commission for supplying at least 400 million doses of its COVID-19 vaccine, AZD1222, if approved.
Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates
by Kinjel Shah
Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).
US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch
by Ritujay Ghosh
The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.